The Oura Ring does not measure blood pressure. It never shows a systolic or diastolic reading in mmHg, and Oura presents its blood pressure features as general wellness tools, not medical devices. As of 3 November 2026, what the ring does offer is a set of trend features. They look for overnight patterns linked to blood pressure and suggest when it may be worth checking with a proper cuff.
What Oura’s blood pressure features do
The features sit in the app’s Heart Health Hub and in Health Radar. Oura’s Heart Health Hub support page describes three parts:
- Blood Pressure Signals analyses nighttime PPG (optical pulse) data in 30-day periods and notifies you only if it detects a pattern that may need a closer look. It needs at least 15 of the past 30 nights of wear to set a baseline.
- Nighttime BP tracks how much your blood pressure dips overnight, based on a 30-night average. Each night is classed as typical dipping (a 10 to 20% drop), reduced (under 10%), pronounced (over 20%) or rising. It shows patterns, not absolute values.
- Cuff Inputs is a log for readings from a real cuff, typed in or imported from Apple Health or Health Connect. Oura labels them using American Heart Association categories, which differ from the thresholds the NHS uses. Cuff readings do not feed into Blood Pressure Signals, Nighttime BP or any Oura score.
The hub also shows Cardiovascular Age and Cardio Capacity (an estimate of VO2 max). These are fitness and ageing estimates, not blood pressure readings.
All of this works on Oura Ring Gen3 and newer, including the Oura Ring 5, which went on sale on 4 June 2026 from £399 according to Tech Advisor. It needs an active membership, which Tech Advisor lists at £5.99 a month or £69.99 a year in the UK. The features launched in the US first. According to Oura’s announcement of 6 October 2026, they then began rolling out to more than 30 further markets, including the UK and every EU country. Oura states that Health Radar is “intended for general wellness purposes only” and is not intended to diagnose, treat or monitor any disease.
Oura’s support page also says that Nighttime BP does not replace blood pressure monitoring or medical care. It is not suitable for managing an existing condition. It warns that a cuff reading is a single daytime snapshot while the ring uses passive overnight data, so the two may not match.
The regulated hypertension feature Oura is still testing
Oura is also studying a separate feature designed to flag possible undiagnosed hypertension, which would be regulated as a medical device. Its Blood Pressure Profile study was announced in October 2025 for US members who test experimental features through Oura Labs, with approval from an institutional review board. As reported by MedTech Dive’s analysis of Oura’s IPO filing in September 2026, the study had more than 350,000 enrolees as of 30 June 2026. The same filing said all of Oura’s current features fall under the FDA’s wellness exemption. As of 3 November 2026, Oura has not announced FDA clearance, or UK or EU approval, for a hypertension feature.
Why the US rules changed in 2026
On 16 September 2025 the FDA issued a safety communication warning against unauthorised blood pressure devices. It named smartwatch and smart ring software features specifically, because inaccurate readings could lead to misdiagnosis or delayed treatment. It told consumers to check the FDA’s 510(k) database, where authorised blood pressure devices generally carry product code DXN.
On 6 January 2026 the FDA revised its general wellness guidance. Non-invasive wearables that estimate blood pressure can now count as low-risk wellness products, as long as they do not claim to diagnose conditions such as hypertension. Oura’s nighttime feature relies on this wellness position, not on FDA clearance.
How a ring differs from a validated cuff
A cuff monitor gives an actual reading in mmHg each time you use it. Optical wearables, including Oura’s ring and the Apple Watch, work differently. They infer blood-pressure-related patterns from changes in the pulse signal picked up by light sensors. Some cuffless devices turn those patterns into estimated readings, usually after calibration against a cuff, as Samsung and Hilo require.
Validated cuffs have passed a published accuracy protocol. The British and Irish Hypertension Society’s list of validated monitors is the list that NICE and NHS England recommend. The BIHS defines wearables as rings, watches and wristbands that take readings without an inflatable cuff. It says it has no validation process for them and so “cannot endorse or approve any wearable blood pressure devices”. It advises patients and clinicians to keep using listed devices.
Wearables with cleared or approved blood pressure features
Regulatory status as of 3 November 2026:
| Device | What it gives you | Needs a cuff | US status | UK and EU status |
|---|---|---|---|---|
| Oura Ring (Gen3, Ring 4, Ring 5) | Overnight dipping trends and pattern alerts, no mmHg readings | No (optional log of cuff readings) | Wellness feature, not FDA-cleared | Wellness feature, rolling out since October 2026 |
| Apple Watch hypertension notifications (Series 9 or later, Ultra 2 or later) | Alert of possible hypertension after 30 days of analysis, no readings | No calibration; a 7-day cuff log is suggested after an alert | FDA-cleared on 11 September 2025 (510(k) K250507) | Launched in more than 150 countries and regions, including the EU; Apple says availability varies by region |
| Samsung Galaxy Watch (Watch4 and later) | Estimated systolic and diastolic readings on demand | Yes, recalibrated every 28 days | Available since spring 2026; Samsung does not describe it as FDA-cleared and says it is not for diagnosis | Samsung Health Monitor app CE-marked in December 2020; offered in the UK since 2021 |
| Hilo bracelet (formerly Aktiia) | Cuffless readings taken through the day | Yes, monthly calibration with the supplied cuff | Aktiia G0 system FDA-cleared for over-the-counter spot checks on 2 July 2025; Hilo Core is sold in the US as a wellness product, not cleared | Bracelet G1 CE-marked as a Class IIa device under the EU MDR; sold in the UK |
| Sky Labs CART BP pro (ring) | Cuffless ring-type blood pressure monitor | Not stated | No FDA authorisation reported | CE-MDR certified; MHRA marketing authorisation reported in May 2026, with sales via prescription planned |
Apple’s feature never shows a reading. Apple’s own hypertension notifications validation paper reports a sensitivity of 41.2%, rising to 53.7% for stage 2 hypertension. Its specificity was 92.3%, in a pivotal study of 2,229 participants. In other words, most people with high blood pressure in the study did not get an alert, and Apple says plainly that not everyone with hypertension will be notified.
The Hilo status is more nuanced than it often appears. Hilo’s own explanation of its FDA position (20 July 2026) says the clearance applies to the Aktiia G0 system, not to Hilo Core as sold in the US.
Withings is often mentioned alongside these. Its blood pressure products, such as the BPM Vision launched in the US in April 2025, are upper-arm cuffs rather than wearables. Withings says the BPM Vision is FDA-cleared and was validated in a 91-person trial.
In Great Britain the MHRA regulates medical devices. On 21 October 2026 the government confirmed it will keep accepting CE-marked medical devices on a long-term basis. This means a device CE-marked for the EU can stay on sale in the UK without a separate UK approval.
What the NHS and British Heart Foundation advise
The NHS blood pressure test page says blood pressure is considered high at 135/85 or above when checked at home, and 140/90 or above when checked by a clinician. For home checks, take a reading, wait one minute and repeat. This is usually done morning and evening for as many days as your doctor or nurse asks. Many pharmacies offer free checks to people aged 40 and over.
The British Heart Foundation’s guide to measuring at home (updated 21 October 2026) advises:
- Use an upper-arm cuff. Use a wrist cuff only if you cannot use an upper-arm one.
- Check that the model appears on the BIHS or STRIDE BP validated list. Basic monitors start at around £20, and your GP may be able to lend you one.
- Make sure the cuff fits, with room for two fingers underneath.
- Sit upright with your back supported, feet flat and arm resting on a table. Do not talk during the reading.
- Take a second reading a few minutes after the first, and a third if the two differ noticeably.
If an Oura or Apple alert prompts you to check, a validated cuff and a conversation with your GP or pharmacist are the right next steps. A wearable alert is not a reason to start, stop or change medication. The FDA’s advice is that anyone whose care depends on accurate readings should ask their healthcare provider for an authorised device.
Sources
- Oura Member Care: Heart Health Hub
- Oura blog: Health Radar and GLP-1 insights expansion (6 October 2026)
- MedTech Dive: 5 takeaways from Oura’s IPO filing
- FDA: Do not use unauthorized devices measuring blood pressure
- Apple: Hypertension Notifications validation paper (September 2025)
- Hilo: Is Hilo Core FDA cleared?
- British and Irish Hypertension Society: BP monitor validations
- GOV.UK: Government confirms indefinite recognition of CE marked medical devices
- NHS: Blood pressure test
- British Heart Foundation: Measuring blood pressure at home


